Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib maintenance versus placebo in platinum-sensitive serous ovarian cancer
ACTRN12609000159257Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in Serous Papillary Cystadenocarcinoma comparing Olaparib maintenance with Matching placebo (2 arms). Primary endpoint: Progression-free survival. Started Aug 2008; status: recruiting.
02
Drugs
olaparib
03
Conditions
Serous Papillary Cystadenocarcinoma
Beyond the preview
Go deeper on ACTRN12609000159257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000159257.